BI 706321 + ustekinumab

BI 706321 + ustekinumab is an investigational combination therapy being studied for the treatment of moderate to severe Crohn's disease. BI 706321 is an oral small molecule drug under development, while ustekinumab is a monoclonal antibody already approved for Crohn's disease and other inflammatory conditions. The combination aims to improve clinical outcomes by targeting different components of the immune system involved in intestinal inflammation. In ongoing phase IIa clinical trials, patients receive daily oral BI 706321 or placebo alongside standard induction and maintenance dosing of subcutaneous or intravenous ustekinumab. The primary objectives are to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy compared to ustekinumab alone[1][4][5][6].